Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 11/20 | 0.50 |
| ▸ | F2 | P00734 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3386016 | 0.93 | CACNB4 (0.46) | F2RF2ALDH1A1KDM4ECYP2C9 | |
| SCHEMBL4316805 | 0.85 | GAA (0.46) | ALDH1A1KDM4ECYP2C9CYP2C19CYP3A4 | |
| SCHEMBL14583991 | 0.79 | SLC22A12 (0.56) | F2RF2CYP2C9HDAC3HDAC1 | |
| SCHEMBL4182812 | 0.76 | POLB (0.48) | ALDH1A1KDM4ECYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4174366 | 0.74 | NPY5R (0.46) | ALDH1A1KDM4EPOLBCYP1A2HPGD | |
| SCHEMBL3386168 | 0.74 | POLB (0.48) | ALDH1A1KDM4ECYP2C9CYP2C19CYP3A4 | |
| SCHEMBL2776874 | 0.71 | ABL1 (0.53) | ALDH1A1MAPT | |
| SCHEMBL25802168 | 0.71 | GAA (0.57) | ALDH1A1KDM4EPOLBCYP1A2MAPT | |
| SCHEMBL16629103 | 0.71 | POLB (0.55) | ALDH1A1CYP2C19POLBCYP2D6MAPT | |
| SCHEMBL29959139 | 0.69 | ABL1 (0.53) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012263-A1 | Process for Production of (1,3-Disubstituted Indolyl)-Urea Derivatives, Intermediates Therefor, and Process for Production of the Intermediates | KOWA COMPANY, LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20090012263-A1 | Process for Production of (1,3-Disubstituted Indolyl)-Urea Derivatives, Intermediates Therefor, and Process for Production of the Intermediates | KOWA COMPANY, LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20090012263-A1 | Process for Production of (1,3-Disubstituted Indolyl)-Urea Derivatives, Intermediates Therefor, and Process for Production of the Intermediates | KOWA COMPANY, LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1806355-A1 | PROCESS FOR PRODUCTION OF (1,3-DISUBSTITUTED INDOLYL)- UREA DERIVATIVES, INTERMEDIATES THEREFOR, AND PROCESS FOR PRODUCTION OF THE INTERMEDIATES | Kowa Company Ltd. (JP) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012263-A1 | Process for Production of (1,3-Disubstituted Indolyl)-Urea Derivatives, Intermediates Therefor, and Process for Production of the Intermediates | WEE1, WASF2, IDO1 | F2R 2248/4885F2 475/4885ALDH1A1 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.